UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS To Receive EY 2018 Master Entrepreneur Award

For more information on the EY Entrepreneur of the Year Awards, please visit ey.com/eoy.

About UroGen Pharma Ltd.

UroGen Pharma Ltd. (URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s lead product candidates, UGN-101 (MitoGel™) and UGN-102 (VesiGel™), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. UroGen is headquartered in Ra’anana, Israel with U.S. headquarters in New York.

Forward-Looking Statements 

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the timing and results of clinical development and commercial prospects of the product candidates in UroGen’s pipeline, including UGN-101 (MitoGel™), and the ability of UroGen to become a leader in the field of uro-oncology, particularly in the treatment of low-grade UTUC, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the potential approval of its first therapy; the ability to obtain and maintain regulatory approval; the scope, progress and expansion of developing and commercializing UroGen’s product candidates; and UroGen’s ability to attract or retain key management and personnel. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of our annual report for the year ended December 31, 2017 filed with the SEC on March 15, 2018 and other filings that UroGen makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.

UROGEN CONTACT:

Kate Bechtold

Director, Corporate Communications & Investor Relations

KateB@urogen.com

914-552-0456

Source : https://finance.yahoo.com/news/urogen-pharma-chairman-arie-belldegrun-120000054.html

2310
UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS To Receive EY 2018 Master Entrepreneur Award

Source:Yahoo Finance

UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS To Receive EY 2018 Master Entrepreneur Award

UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS To Receive EY 2018 Master Entrepreneur Award

Source:GlobeNewswire

UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS To Receive EY 2018 Master Entrepreneur Award